Abstracts tagged "Comparative effectiveness and harms"

Abstract Number: 47 • 2015 ACR/ARHP Annual Meeting
Use of Social Media Data for Comparative Effectiveness and Safety Research: An Example from Rheumatoid Arthritis
Jeffrey R. Curtis^1,2, James Willig³, Monica Safford¹, Joseph Coe⁴, Kaitlin O'Hara⁵ and Rosee Sa'adon⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama-Birmingham, Birmingham, AL, ³Med - Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, ⁴Creaky Joints/Global Healthy Living Foundatio, Upper Nyack, NY, ⁵Treato Ltd., Princeton, NJ, ⁶Treato, Ltd., Or-Yehuda, Israel
Background/Purpose: The data sources available to answer comparative effectiveness and safety questions shortly after medication licensure may be limited. Social media may provide a unique…
Abstract Number: 505 • 2015 ACR/ARHP Annual Meeting
Comparative Effectiveness and Time to Response Among Abatacept, Adalimumab, Certolizumab, Etanercept, Infliximab, Rituximab and Tocilizumab in a Real World Routine Care Registry
Yusuf Yazici¹, Hannah Bernstein¹ and Christopher Swearingen², ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Pediatrics & Biostatistics, University of Arkansas, Little Rock, AR
Background/Purpose: With the availability of multiple biologic agents, each with different modes of action, use of real world registries provide the manner in which to…
Abstract Number: 1043 • 2015 ACR/ARHP Annual Meeting
Enhancing Comparative Effectiveness Research By Combining Observational and Randomized Trial Data to Personalize the Choice Between Methotrexate and Triple Therapy for Methotrexate-Naïve Patients with Early Rheumatoid Arthritis
Glen S. Hazlewood^1,2, Cheryl Barnabe³, Gilles Boire⁴, Carol Hitchon⁵, Edward C. Keystone⁶, Boulos Haraoui⁷, J Carter Thorne⁸, Diane Tin⁹, Janet E. Pope¹⁰, Daming Lin¹¹, VP Bykerk¹² and CATCH investigators, ¹Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Institut de Rhumatologie, Montreal, QC, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹²Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Randomized controlled trials (RCTs) are considered the gold standard for comparing efficacy of treatments, but the results may be less generalizable to clinical practice…
Abstract Number: 1044 • 2015 ACR/ARHP Annual Meeting
Many Patients with Early Rheumatoid Arthritis Want Triple Therapy: An Analysis Combining Comparative Effectiveness Research and Patients Preferences to Inform Treatment Recommendations
Glen S. Hazlewood^1,2, Claire Bombardier³, George A. Tomlinson⁴ and Deborah Marshall⁵, ¹Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴Medicine, University Health Network, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada
Background/Purpose: Growing evidence supports the efficacy of triple therapy (methotrexate + sulphasalazine + hydroxychloroquine) for controlling disease activity in patients with early rheumatoid arthritis (ERA),…
Abstract Number: 1221 • 2015 ACR/ARHP Annual Meeting
Characteristics and Outcomes of RA Patients Who Start Biosimilar Infliximab in South Korea
Yoon-Kyoung Sung¹, Soo-Kyung Cho¹, Soyoung Won², Chan-Bum Choi³, So-Young Bang⁴, Seung-Jae Hong⁵, Hyoun-Ah Kim⁶, Eunmi Koh⁷, Hye-Soon Lee⁸, Chang-Hee Suh⁹, Dae-Hyun Yoo¹⁰, Sang-Cheol Bae¹ and BIOPSY investigators, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ²Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ³Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Hanyang University Guri Hospital, Guri, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Kyung Hee University Hospital, Seoul, South Korea, ⁶Ajou University Hospital, Suwon, South Korea, ⁷Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁸Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ⁹Department of Rheumatology, Ajou University Hospital, Suwon, South Korea, ¹⁰Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Recently biosimilar infliximab was approved in South Korea and it has been commonly used for rheumatoid arthritis (RA) patients who are resistant to conventional…
Abstract Number: 1414 • 2015 ACR/ARHP Annual Meeting
Comparison of Surgical and Conservative Therapy of Lumbar Disc Herniation with Radicular Signs and Symptoms in a Quality Management Program
Marinella Gugliotta¹, Bruno R. da Costa², Essam Dabis³, Robert Theiler⁴, Stephan Reichenbach², Peter Jüni², Hans Landolt¹ and Paul Hasler³, ¹Neurosurgery, Kantonsspital Aarau, Aarau, Switzerland, ²Clinical Epidemiology and Biostatistics, University of Bern, Bern, Switzerland, ³Rheumatology, Kantonsspital Aarau, Aarau, Switzerland, ⁴Rheumatology, Stadtspital Triemli, Zürich, Switzerland
Background/Purpose: Current evidence for outcomes of surgical versus conservative treatment of lumbar disc herniation with nerve root compression is ambiguous. To compare the effectiveness of…
Abstract Number: 1433 • 2015 ACR/ARHP Annual Meeting
Predicting Response to Osteoarthritis Treatment Based on Patient Reported Outcome Measures and Quantitative Sensory Testing
Kristine Phillips¹, David A. Williams², Arnold Gammaitoni³, J. Ryan Scott⁴, Steven E. Harte⁴, Susan L. Murphy⁵ and Daniel J. Clauw⁶, ¹Internal Medicine, University of Michigan, Ann Arbor, MI, ²Anesthseiology, University of Michigan, Ann Arbor, MI, ³Zogenix, Inc, San Diego, CA, ⁴Department of Anesthesiology, University of Michigan, Ann Arbor, MI, ⁵Phyiscal Medicine & Rehabilitation, University of Michigan, Ann Arbor, MI, ⁶Anesthesiology, University of Michigan, Ann Arbor, MI
Background/Purpose: Recent studies have suggested that a subset of individuals with arthritis have a component of sensitization to their pain. This subset of patients with…
Abstract Number: 2102 • 2015 ACR/ARHP Annual Meeting
Higher Persistence and Adherence with Combination Therapy with Tumor Necrosis Factor Inhibitor+Methotrexate Combination Versus Triple Therapy in US Veterans with Rheumatoid Arthritis
Brian Sauer¹, Chia-Chen Teng², Jianwei Leng³, Ted R. Mikuls⁴, Jeffrey R. Curtis⁵, Bradley S. Stolshek⁶, Derek Tang⁶ and Grant W. Cannon⁷, ¹IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ²HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Internal Medicine Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Amgen, Inc., Thousand Oaks, CA, ⁷Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT

Background/Purpose: Randomized controlled trials in RA have reported efficacy with both triple therapy (methotrexate [MTX] + hydroxychloroquine [HCQ] + sulfasalazine [SSZ]) and tumor necrosis factor…
Abstract Number: 2365 • 2014 ACR/ARHP Annual Meeting
Comparison of the Effects of a Pharmaceutical Industry Decision Guide and Decision Aids on Patient Choice to Intensify Rheumatoid Arthritis Therapy with Etanercept
Richard Martin¹, Ryan Enck², Andrew J. Head³, James Birmingham¹ and Aaron T. Eggebeen⁴, ¹Medicine, Rheumatology, Michigan State University, College of Human Medicine, Grand Rapids, MI, ²Michigan State University College of Human Medicine, Grand Rapids, MI, ³Medicine, Rheumatology, College of Human Medicine, Michigan State University, Grand Rapids, MI, ⁴Medicine, Rheumatology, Michigan State University College of Human Medicine, Grand Rapids, MI
Background/Purpose: To evaluate the comparative effects of a pharmaceutical industry decision guide (Pharm Booklet) and International Patient Decision Aids Standard (IPDAS) compliant patient decision aids…
Abstract Number: 2293 • 2014 ACR/ARHP Annual Meeting
Preliminary Results from the Childhood Arthritis and Rheumatology Research Alliance Systemic JIA Consensus Treatment Plans Pilot Study
Yukiko Kimura¹, Esi Morgan-DeWitt², Kelly L. Mieszkalski³, Thomas Brent Graham⁴, Timothy Beukelman⁵, Maria F. Ibarra⁶, Norman T. Ilowite⁷, Marisa S. Klein-Gitelman⁸, Karen Onel⁹, Sampath Prahalad¹⁰, Marilynn G. Punaro¹¹, Sarah Ringold¹², Dana Toib¹³, Heather Van Mater¹⁴, Pamela F. Weiss¹⁵ and Laura Schanberg¹⁶, ¹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Pediatric rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Dept of Pediatrics, Duke University Medical Center, Durham, NC, ⁴Pediatric Rheumatology, Vanderbilt Children's Hospital, Nashville, TN, ⁵Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, ⁷Pediatrics, Albert Einstein College of Medicine, Bronx, NY, ⁸Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁹Division of Pediatric Rheumatology, University of Chicago, Chicago, IL, ¹⁰Emory University School of Medicine, Atlanta, GA, ¹¹Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, ¹²Seattle Children's Hospital, Seattle, WA, ¹³St. Christopher's Hospital for Children, Philadelphia, PA, ¹⁴Duke Pediatric Rheumatology, Duke University Medical Center, Hillsborough, NC, ¹⁵Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁶Duke University, Durham, NC
Background/Purpose: Treatment options for systemic JIA (sJIA) have recently expanded to include IL1 and IL6 inhibitors in addition to traditional treatments such as glucocorticoids (GC)…
Abstract Number: 494 • 2014 ACR/ARHP Annual Meeting
Estimation of Cost per Effectively Treated Patients with Biologic Disease Modifying Anti-Rheumatic Drugs in US Veterans with Rheumatoid Arthritis
Grant W. Cannon¹, Chia-Chen Teng², Tao He², Jianwei Leng³, Chao-Chin Lu², Derek Tang⁴, Neel Shah⁵, David J. Harrison⁴ and Brian Sauer², ¹Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Salt Lake City VA and University of Utah, Salt Lake City, UT, ³Salt Lake City VA and University of Utah, Salt Lake Citty, UT, ⁴Amgen Inc., Thousand Oaks, CA, ⁵1 Amgen Center Dr, Amgen Inc., Thousand Oaks, CA
Background/Purpose: An algorithm based on administrative claims data (in lieu of clinical measures) was validated using data from the Veteran’s Affairs (VA) Rheumatoid Arthritis (RA)…
Abstract Number: L20 • 2014 ACR/ARHP Annual Meeting
BOW015, a Biosimilar Infliximab, in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses: 54-Week Results of a Randomized, Double-Blind, Active Comparator Study
Jonathan Kay¹, Michael Wyand², Srikantiah Chandrashekara³, Davy Jacob Olakkengil⁴, Kaushik Bhojani⁵, Girish Bhatia⁶, Gaurav Rathi⁷, Suresh Maroli⁸, Elizabeth Thomson⁹, Cheryl Lassen¹⁰, Lucy Shneyer¹¹ and Arvind Chopra¹², ¹UMass Memorial Medical Center, Worcester, MA, ²Epirus Biopharmaceuticals, Boston, MA, ³Chanre Rheumatology and Immunology Centre and Research, Bangalore, India, ⁴St. John’s Medical College Hospital, Bengaluru, India, ⁵Department of Rheumatology, Fortis Hospital, Mumbai, India, ⁶Pentagon Multispeciality Clinic and Research Centre, Pune, India, ⁷Rathi Hospital, Ahmedabad, India, ⁸Reliance Life Sciences, Mumbai, India, ⁹Elizabeth Thomson LTD, London, MA, United Kingdom, ¹⁰Epirus Biopharmaceuticals, Zug, Switzerland, ¹¹Shneyer Statistics LLC, Denville, NJ, ¹²Rheumatology, Center for Rheumatic Diseases, Pune, India
Background/Purpose: Over the first 16 wks of this phase 3 double-blind (DB) comparative effectiveness clinical trial, the comparable proportion of ACR20 responders for BOW015 (a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].